Page 37 - TD-4-3

Tumor Discovery Immunomodulatory effects of CDK4/6 inhibitors

doi: 10.1158/1078-0432.CCR-23-0749 The immunoADAPT study (NCT03573648). Cancer Res.
2019;79(4 Suppl):OT3-02-03.
53. Kollmann K, Heller G, Schneckenleithner C, et al. A kinase-
independent function of CDK6 links the cell cycle to tumor doi: 10.1158/1538-7445.SABCS18-OT3-02-03
angiogenesis. Cancer Cell. 2016;30(2):359-360. 63. Zavras P, Chen R, Qi H, et al. Abstract PO1-01-09:
doi: 10.1016/j.ccell.2016.07.003 Neoadjuvant endocrine therapy and avelumab with or
without palbociclib in stage II/III endocrine receptor-
54. Huang Z, Zhao B, Qin Z, et al. Novel dual inhibitors positive breast cancer: The immunoADAPT trial. Cancer
targeting CDK4 and VEGFR2 synergistically suppressed Res. 2024;84(9 Suppl):PO1-01-09.
cancer progression and angiogenesis. Eur J Med Chem.
2019;181:111541. doi: 10.1158/1538-7445.SABCS23-PO1-01-09
doi: 10.1016/j.ejmech.2019.07.044 64. Garrido-Castro AC, Graham N, Ali LR, et al. Phase I
study of ribociclib (CDK4/6 inhibitor) with spartalizumab
55. Liu R, Li HF, Li S. PD-1-mediated inhibition of T (PD-1 inhibitor) with and without fulvestrant in metastatic
cell activation: Mechanisms and strategies for cancer hormone receptor-positive breast cancer or advanced
combination immunotherapy. Cell Insight. 2024;3(2):100146. ovarian cancer. J Immunother Cancer. 2025;13(2):e010430.
doi: 10.1016/j.cellin.2024.100146 doi: 10.1136/jitc-2024-010430
56. Zhang J, Bu X, Wang H, et al. Cyclin D-CDK4 kinase 65. Masuda J, Sakai H, Tsurutani J, et al. Efficacy, safety, and
destabilizes PD-L1 via cullin 3-SPOP to control cancer biomarker analysis of nivolumab in combination with
immune surveillance. Nature. 2018;553(7686):91-95. abemaciclib plus endocrine therapy in patients with
doi: 10.1038/nature25015 HR-positive HER2-negative metastatic breast cancer:
A phase II study (WJOG11418B NEWFLAME trial).
57. Shrestha M, Wang DY, Ben-David Y, Zacksenhaus E. J Immunother Cancer. 2023;11(9):e007126.
CDK4/6 inhibitors and the pRB-E2F1 axis suppress PVR
and PD-L1 expression in triple-negative breast cancer. doi: 10.1136/jitc-2023-007126
Oncogenesis. 2023;12(1):29. 66. Mayer EL, Ren Y, Wagle N, et al. PACE: A randomized
doi: 10.1038/s41389-023-00475-1 phase II study of fulvestrant, palbociclib, and avelumab after
progression on cyclin-dependent kinase 4/6 inhibitor and
58. Palicelli A, Croci S, Bisagni A, et al. What do we have to aromatase inhibitor for hormone receptor-positive/human
know about PD-L1 expression in prostate cancer? A epidermal growth factor receptor-negative metastatic breast
systematic literature review. Part 4: Experimental treatments cancer. J Clin Oncol. 2024;42(17):2050-2060.
in pre-clinical studies (cell lines and mouse models). Int J
Mol Sci. 2021;22(22):12297. doi: 10.1200/JCO.23.01940
doi: 10.3390/ijms222212297 67. Kearney MR, McGuinness JE, Kalinsky K. Clinical trial data
and emerging immunotherapeutic strategies: Hormone
59. Jerusalem G, Prat A, Salgado R, et al. Neoadjuvant receptor-positive, HER2- negative breast cancer. Breast
nivolumab + palbociclib + anastrozole for oestrogen Cancer Res Treat. 2021;189(1):1-13.
receptor-positive/human epidermal growth factor receptor
2-negative primary breast cancer: Results from checkMate doi: 10.1007/s10549-021-06291-8
7A8. Breast. 2023;72:103580. 68. Lelliott EJ, Sheppard KE, McArthur GA. Harnessing
doi: 10.1016/j.breast.2023.103580 the immunotherapeutic potential of CDK4/6 inhibitors
in melanoma: Is timing everything? NPJ Precis Oncol.
60. Rugo HS, Kabos P, Beck JT, et al. Abemaciclib in combination 2022;6(1):26.
with pembrolizumab for HR+, HER2- metastatic breast
cancer: Phase 1b study. NPJ Breast Cancer. 2022;8(1):118. doi: 10.1038/s41698-022-00273-9
doi: 10.1038/s41523-022-00482-2 69. Xue Y, Zhai J. Strategy of combining CDK4/6 inhibitors with
other therapies and mechanisms of resistance. Int J Clin Exp
61. Yuan Y, Lee JS, Yost SE, et al. Phase I/II trial of palbociclib, Pathol. 2024;17(7):189-207.
pembrolizumab and letrozole in patients with hormone
receptor-positive metastatic breast cancer. Eur J Cancer. doi: 10.62347/HGNI4903
2021;154:11-20. 70. Shim SH, Lee JY, Lee YY, et al. Major clinical research
doi: 10.1016/j.ejca.2021.05.035 advances in gynecologic cancer in 2023: A tumultuous year
for endometrial cancer. J Gynecol Oncol. 2024;35(2):e66.
62. Santa-Maria C, Wang C, Cimino-Mathews A, et al.
Abstract OT3-02-03: IMMUNe mOdulation in early doi: 10.3802/jgo.2024.35.e66
stage estrogen receptor positive breast cancer treated 71. Wang Y, Liu L, Graff SL, Cheng L. Recent advancements in
with neoADjuvant avelumab, palbociclib, and tamoxifen: biomarkers and molecular diagnostics in hormonal receptor-

Volume 4 Issue 3 (2025) 29 doi: 10.36922/TD025190037